Hematopoietic cell transplantation for telomere biology diseases: A retrospective single-center cohort study.
dyskeratosis congenita
hematopoietic cell transplant
telomere biology disease
telomeres
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
revised:
24
05
2023
received:
27
03
2023
accepted:
26
05
2023
medline:
7
8
2023
pubmed:
1
6
2023
entrez:
1
6
2023
Statut:
ppublish
Résumé
Telomere biology diseases (TBD) result from defective telomere maintenance, leading to bone marrow failure. The only curative treatment for aplastic anemia related to TBD is a hematopoietic cell transplant (HCT). Although reduced-intensity conditioning (RIC) regimens decrease transplant-related mortality, non-hematological phenotypes represent a major challenge and are associated with poor long-term follow-up outcomes. To describe the outcome of TBD patients transplanted for marrow failure. This is a retrospective, single-center study describing the outcomes of 32 consecutive transplants on 29 patients between 1993 and 2019. The median age at transplantation was 14 years (range, 3-30 years). Most patients received a RIC regimen (n = 28) and bone marrow (BM) from an unrelated donor (n = 16). Four patients received a haploidentical transplant. Chimerism was available for 27 patients with a median time to neutrophil recovery of 20 days (13-36 days). Primary graft failure occurred in one patient, whereas second graft failure occurred in two. Acute GVHD grade II-IV and moderate to severe chronic GVHD occurred in 22% of patients at risk. Fourteen patients were alive after HCT at the last follow-up (median, 6 years; 1.4-19 years). The 5-year overall survival was better after matched sibling donor (MSD) transplantation compared to other hematopoietic stem cell sources (88.9% vs. 47.7%; p = .05; CI = 95%). Overall, 15 patients died after HCT, most of them (n = 11) after the first year of transplant, due to non-hematological disease progression or complication of chronic GVHD. Hematopoietic cell transplantation is a potentially curative treatment option for TBD, nonetheless the poor outcome reflects the progression of non-hematologic disease manifestations, which should be considered when transplantation is indicated.
Sections du résumé
BACKGROUND
BACKGROUND
Telomere biology diseases (TBD) result from defective telomere maintenance, leading to bone marrow failure. The only curative treatment for aplastic anemia related to TBD is a hematopoietic cell transplant (HCT). Although reduced-intensity conditioning (RIC) regimens decrease transplant-related mortality, non-hematological phenotypes represent a major challenge and are associated with poor long-term follow-up outcomes.
OBJECTIVE
OBJECTIVE
To describe the outcome of TBD patients transplanted for marrow failure.
STUDY DESIGN
METHODS
This is a retrospective, single-center study describing the outcomes of 32 consecutive transplants on 29 patients between 1993 and 2019.
RESULTS
RESULTS
The median age at transplantation was 14 years (range, 3-30 years). Most patients received a RIC regimen (n = 28) and bone marrow (BM) from an unrelated donor (n = 16). Four patients received a haploidentical transplant. Chimerism was available for 27 patients with a median time to neutrophil recovery of 20 days (13-36 days). Primary graft failure occurred in one patient, whereas second graft failure occurred in two. Acute GVHD grade II-IV and moderate to severe chronic GVHD occurred in 22% of patients at risk. Fourteen patients were alive after HCT at the last follow-up (median, 6 years; 1.4-19 years). The 5-year overall survival was better after matched sibling donor (MSD) transplantation compared to other hematopoietic stem cell sources (88.9% vs. 47.7%; p = .05; CI = 95%). Overall, 15 patients died after HCT, most of them (n = 11) after the first year of transplant, due to non-hematological disease progression or complication of chronic GVHD.
CONCLUSIONS
CONCLUSIONS
Hematopoietic cell transplantation is a potentially curative treatment option for TBD, nonetheless the poor outcome reflects the progression of non-hematologic disease manifestations, which should be considered when transplantation is indicated.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
423-431Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Sarek G, Marzec P, Margalef P, Boulton SJ. Molecular basis of telomere dysfunction in human genetic diseases. Nat Struct Mol Biol. 2015;22(11):867-874.
Armando RG, Mengual DL, Gomez DE. Telomeropathies: etiology, diagnosis, treatment and follow-up. Ethical and legal considerations. Clin Genet. 2019;96(1):3-16.
Townsley DM, Dumitriu B, Young NS. Bone marrow failure and the telomeropathies. Blood. 2014;124:2775-2783.
Vulliamy T, Marrone A, Szydlo R, Walne A, Mason PJ, Dokal I. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet. 2004;36:447-449.
Armanios M, Chen JL, Chang YPC, et al. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci U S A. 2005;102:1-5.
Marrone A, Walne A, Dokal I. Dyskeratosis congenita: telomerase, telomeres and anticipation. Curr Opin Genet Dev. 2005;2005(15):249-257.
Walne AJ, Marrone A, Dokal I. Dyskeratosis congenita: a disorder of defective telomere maintenance? Int J Hematol. 2005;82:184-189.
Vulliamy TJ, Marrone A, Knight SW, Walne A, Mason PJ, Dokal I. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood. 2019;107:2680-2686.
Calado RT, Young NS. Telomere diseases. N Engl J med. 2009;361:2353-2365.
Alter BP, Baerlocher GM, Savage SA, et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood. 2019;110(5):1439-1448.
Vulliamy TJ, Knight SW, Mason PJ, Dokal I. Very short telomeres in the peripheral blood of patients with X-linked and autosomal dyskeratosis congenita. Blood Cells Mol Dis. 2001;27:353-357.
Brümmendorf TH, Maciejewski JP, Mak J, et al. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood. 2001;97:895-900.
Hoyeraal HM, Lamvik J, Moe PJ. Congenital hypoplastic thrombocytopenia and cerebral malformations In two brothers. Acta Paediatr Scand. 1970;59(2):185-191.
Khincha PP, Ingrid M, Giri N, et al. Response to androgen therapy in patients with dyskeratosis congenita. Br J Haematol. 2014;165(3):349-357.
Calado RT, Yewdell WT, Wilkerson KL, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood. 2018;114:2236-2244.
Khincha PP, Bertuch AA, Gadalla SM, Giri N, Alter BP, Savage SA. Similar telomere attrition rates in androgen-treated and untreated patients with dyskeratosis congenita. Blood Adv. 2018;2:1243-1249.
Latour RP, Porcher R, Dalle J, et al. Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. Blood. 2019;122:4279-4287.
Fioredda F, Iacobelli S, Korthof ET, et al. Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita. Br J Haematol. 2018;183:110-118.
Kojima S. Reconsidering the indication of haematopoietic stem cell transplantation for dyskeratosis congenita. Br J Haematol. 2018;1:11-12.
Dalle JH, Latour RP. Allogeneic hematopoietic stem cell transplantation for inherited bone marrow failure syndromes. Int J Hematol. 2016;103:373-379.
Elmahadi S, Muramatsu H, Kojima S. Allogeneic hematopoietic stem cell transplantation for dyskeratosis congenita. Curr Opin Hematol. 2016;23:501-507.
Dokal I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program. 2011;2011:480-486.
Vulliamy T, Dokal I. Dyskeratosis congenita. Semin Hematol. 2006;43:157-166.
Gutierrez-Rodrigues F, Santana-Lemos BA, Scheucher PS, Alves-Paiva RM, Calado RT. Direct comparison of flow-FISH and qPCR as diagnostic tests for telomere length measurement in humans. PLoS One. 2014;9:1-9.
Gutierrez-Rodrigues F, Alves-Paiva RM, Scatena NF, et al. Association between leukocyte telomere length and sex by quantile regression analysis. Hematol Transfus Cell Ther. 2022;44(3):346-351.
Catto LFB, Borges G, Pinto AL, et al. Somatic genetic rescue in hematopoietic cells in GATA2 deficiency. Blood. 2020;136:1002-1005.
Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97(4):855-864.
Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-955.
Ozdemir ZN, Civriz S. Transfusion and apheresis science graft failure after allogeneic hematopoietic stem cell transplantation. Transfus Apher Sci. 2018;57(2):163-167.
Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in dyskeratosis congenita. Blood. 2009;113:6549-6557.
Giri N, Lee R, Faro A, et al. Lung transplantation for pulmonary fibrosis in dyskeratosis congenita: case report and systematic literature review. BMC Blood Disord. 2011;11:3.
Jillella AP, Shafer D, Klumpp TR, Emmons RVB, Mangan KF. Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism. Am J Hematol. 2007;426:419-426.
Oshrine BR, Olson TS. Mixed chimerism and graft loss in pediatric recipients of an alemtuzumab-based reduced-intensity conditioning regimen for non-malignant disease. Pediatr Blood Cancer. 2014;61(10):1852-1859.
Nishio N, Takahashi Y, Ohashi H, et al. Reduced-intensity conditioning for alternative donor hematopoietic stem cell transplantation in patients with dyskeratosis congenita. Pediatr Transplant. 2011;15:161-166.
Gorgy AI, Jonassaint NL, Stanley SE, et al. Hepatopulmonary syndrome is a frequent cause of dyspnea in the short telomere disorders. Chest. 2015;148:1019-1026.
Berthou C, Devergie A, D'Agay MF, et al. Late vascular complications after bone marrow transplantation for dyskeratosis congênita. Br J Haematol. 1991;79:335-336.
Brazzola P, Duval M, Fournet JC, et al. Fatal diffuse capillaritis after hematopoietic stem-cell transplantation for dyskeratosis congenita despite low-intensity conditioning regimen. Bone Marrow Transpl. 2005;36:1103-1105.
Rocha V, Devergie A, Socié G, et al. Unusual complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol. 1998;103:243-248.
Bonfim C, Ribeiro L, Nichele S, et al. Haploidentical bone marrow transplantation with post-transplant cyclophosphamide for children and adolescents with Fanconi. Biol Blood Marrow Transplant. 2017;23:310-317.
Barbaro P, Vedi A. Survival following haematopoietic stem cell transplant in patients with dyskeratosis congenita-a systematic review of the literature. Biol Blood Marrow Transplant. 2016;22:1152-1158.